WOCKPHARMA

Wockhardt Share Price

₹1,300.8
-9.15 (-0.7%)
05 November, 2024 12:54 BSE: 532300 NSE: WOCKPHARMA ISIN: INE049B01025

Start SIP in Wockhardt

Start SIP

Wockhardt Performance

Day Range

  • Low 1,263
  • High 1,319
₹ 1,300

52 Week Range

  • Low 232
  • High 1,319
₹ 1,300
  • Open Price1,315
  • Previous Close1,310
  • Volume564296

Wockhardt Chart

  • Over 1 Month + 33.61%
  • Over 3 Month + 43.42%
  • Over 6 Month + 132.37%
  • Over 1 Year + 440.43%

Wockhardt Key Statistics

P/E Ratio -58.2
PEG Ratio -1.3
Market Cap Cr 19,957
Price to Book Ratio 5.5
EPS -26.6
Dividend 0
Relative Strength Index 73.74
Money Flow Index 79.51
MACD Signal 37.31
Average True Range 57.56

Wockhardt Investment Rating

  • Master Rating:
  • Wockhardt Ltd. is a global pharmaceutical and biotechnology company specializing in the development, manufacturing, and marketing of medicines, vaccines, and biosimilars. It focuses on key therapeutic areas including anti-infectives, cardiology, and diabetes care. Wockhardt has an operating revenue of Rs. 2,893.00 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -15% needs improvement, ROE of -13% is poor and needs improvement. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 17% and 66% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 13% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 36 which is a POOR score indicating inconsistency in earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 28 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Wockhardt Financials
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 352355288260251291
Operating Expenses Qtr Cr 272401263270256321
Operating Profit Qtr Cr 80-4625-10-5-30
Depreciation Qtr Cr 434543444445
Interest Qtr Cr 585961595858
Tax Qtr Cr 0000010
Net Profit Qtr Cr 6-126-74-107-115-299
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 1,1951,139
Operating Expenses Annual Cr 1,1901,002
Operating Profit Annual in Cr -3670
Depreciation Cr 176186
Interest Annual Cr 237229
Tax Annual Cr 0-47
Net Profit Annual Cr -422-466
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 18871
Cash from Investing Activity Annual Cr -75-3
Cash from Financing Annual Activity Cr 346-236
Net Cash Flow Annual Cr 459-168
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 1,7961,753
Fixed Assets Annual Cr 2,2822,448
Total Non Current Assets Annual Cr 3,0893,257
Total Current Assets Annual Cr 1,7791,475
Total Assets Annual Cr 4,8684,732
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 117122
ROE Annual % -23-27
ROCE Annual % -6-2
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 013
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 739700701753644678
Operating Expenses Qtr Cr 648803664681628675
Operating Profit Qtr Cr 91-1033772163
Depreciation Qtr Cr 545855555556
Interest Qtr Cr 737377767976
Tax Qtr Cr 10-3-1381844
Net Profit Qtr Cr -14-169-83-77-134-208
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 2,8812,773
Operating Expenses Annual Cr 2,7592,550
Operating Profit Annual in Cr 39101
Depreciation Cr 223251
Interest Annual Cr 305302
Tax Annual Cr 52-3
Net Profit Annual Cr -463-559
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 219153
Cash from Investing Activity Annual Cr -137-125
Cash from Financing Annual Activity Cr 334-315
Net Cash Flow Annual Cr 416-287
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 3,3593,354
Fixed Assets Annual Cr 3,6503,636
Total Non Current Assets Annual Cr 5,4655,475
Total Current Assets Annual Cr 2,1842,208
Total Assets Annual Cr 7,6497,683
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 238254
ROE Annual % -14-17
ROCE Annual % -2-1
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 48

Wockhardt Technicals

EMA & SMA

Current Price
₹1,300.8
-9.15 (-0.7%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹1,111.92
  • 50 Day
  • ₹1,036.06
  • 100 Day
  • ₹934.57
  • 200 Day
  • ₹777.35
  • 20 Day
  • ₹1,084.96
  • 50 Day
  • ₹1,042.20
  • 100 Day
  • ₹932.38
  • 200 Day
  • ₹733.74

Wockhardt Resistance and Support

PIVOT
₹1,289.22
Resistance
First Resistance 1,333.43
Second Resistance 1,356.92
Third Resistance 1,401.13
RSI 73.74
MFI 79.51
MACD Single Line 37.31
MACD 60.64
Support
First Support 1,265.73
Second Support 1,221.52
Third Supoort 1,198.03

Wockhardt Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,462,229 66,355,952 45.38
Week 904,608 41,204,913 45.55
1 Month 594,160 30,159,547 50.76
6 Month 551,270 35,132,438 63.73

Wockhardt Result Highlights

Wockhardt Synopsis

NSE-Medical-Generic Drugs

Wockhardt Ltd. is a leading global pharmaceutical and biotechnology company engaged in the research, development, and manufacturing of a wide range of medicines, vaccines, and biosimilars. The company’s product portfolio spans critical therapeutic areas such as anti-infectives, cardiology, diabetes, respiratory, and pain management. Wockhardt operates state-of-the-art manufacturing and R&D facilities in India, the UK, Ireland, and the US, adhering to international quality standards. With a strong emphasis on innovation, Wockhardt invests significantly in developing novel drug formulations and biotechnology products. The company is committed to improving patient health worldwide through advanced, affordable, and high-quality healthcare solutions.
Market Cap 20,098
Sales 1,255
Shares in Float 7.36
No of funds 141
Yield
Book Value 11.22
U/D Vol ratio 2.1
LTDebt / Equity 50
Alpha 0.58
Beta 1.34

Wockhardt Shareholding Pattern

Owner NameSep-24Jun-24Mar-24Dec-23
Promoters 51.99%51.99%51.6%54.93%
Mutual Funds 2.95%2.91%3.11%0.09%
Insurance Companies
Foreign Portfolio Investors 6.7%5.94%5.49%4.18%
Financial Institutions/ Banks
Individual Investors 29.02%30.18%29.93%32.94%
Others 9.34%8.98%9.87%7.86%

Wockhardt Management

Name Designation
Dr. Habil Khorakiwala Founder Chairman
Dr. Murtaza Khorakiwala Managing Director
Dr. Huzaifa Khorakiwala Executive Director
Ms. Zahabiya Khorakiwala Non Executive Director
Mrs. Tasneem Mehta Independent Director
Mr. Vinesh Kumar Jairath Independent Director
Mr. Akhilesh Gupta Independent Director
Ms. Amelia Fernandes Independent Director
Mr. Ahmad Javed Independent Director

Wockhardt Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Wockhardt Corporate Action

Date Purpose Remarks
2024-08-09 Quarterly Results
2024-05-28 Audited Results
2024-03-26 Others Inter alia, to consider and determine the issue price of Equity Shares to be issued pursuant to the Issue, including any discount, not more than 5%, on the floor price. issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-.
2024-02-14 Quarterly Results
2023-11-14 Quarterly Results

Wockhardt FAQs

What is Share Price of Wockhardt ?

Wockhardt share price is ₹1,300 As on 05 November, 2024 | 12:40

What is the Market Cap of Wockhardt ?

The Market Cap of Wockhardt is ₹19957.2 Cr As on 05 November, 2024 | 12:40

What is the P/E ratio of Wockhardt ?

The P/E ratio of Wockhardt is -58.2 As on 05 November, 2024 | 12:40

What is the PB ratio of Wockhardt ?

The PB ratio of Wockhardt is 5.5 As on 05 November, 2024 | 12:40

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23